

## Halaven Approval Status Worldwide (Country/ Region)

April, 2019

### Breast Cancer 3rd line

|                        |          |               |          |              |          |             |          |
|------------------------|----------|---------------|----------|--------------|----------|-------------|----------|
| Australia              | Aug-2012 | Hungary       | Mar-2011 | Morocco      | Dec-2014 | Sri Lanka   | Jan-2019 |
| Austria                | Mar-2011 | Iceland       | Mar-2011 | Myanmar      | Dec-2013 | Sweden      | Mar-2011 |
| Bahrain                | Jun-2016 | India         | Apr-2013 | Netherlands  | Mar-2011 | Switzerland | May-2011 |
| Belgium                | Mar-2011 | Indonesia     | Dec-2015 | Norway       | Mar-2011 | Taiwan      | Aug-2013 |
| Bosnia and Hercegovina | Jul-2013 | Ireland       | Mar-2011 | Oman         | Nov-2016 | Thailand    | Dec-2012 |
| Brazil                 | May-2013 | Israel        | May-2012 | Pakistan     | Jan-2019 | UAE         | Jan-2015 |
| Brunei                 | Dec-2018 | Italy         | Mar-2011 | Philippines  | Mar-2013 | UK          | Mar-2011 |
| Bulgaria               | Mar-2011 | Japan         | Apr-2011 | Poland       | Mar-2011 | US          | Nov-2010 |
| Cambodia               | Oct-2017 | Jordan        | May-2014 | Portugal     | Mar-2011 |             |          |
| Canada                 | Dec-2011 | Kuwait        | Oct-2012 | Qatar        | Aug-2017 |             |          |
| Croatia                | Jun-2012 | Laos          | Sep-2013 | Romania      | Mar-2011 |             |          |
| Cyprus                 | Mar-2011 | Latvia        | Mar-2011 | Russia       | Jul-2012 |             |          |
| Czech Republic         | Mar-2011 | Lebanon       | May-2013 | Saudi Arabia | Nov-2014 |             |          |
| Denmark                | Mar-2011 | Liechtenstein | Mar-2011 | Serbia       | Aug-2013 |             |          |
| Estonia                | Mar-2011 | Lithuania     | Mar-2011 | Singapore    | Feb-2011 |             |          |
| Finland                | Mar-2011 | Luxembourg    | Mar-2011 | Slovakia     | Mar-2011 |             |          |
| France                 | Mar-2011 | Macau         | Jun-2012 | Slovenia     | Mar-2011 |             |          |
| Germany                | Mar-2011 | Malaysia      | Sep-2012 | South Africa | Jul-2016 |             |          |
| Greece                 | Mar-2011 | Malta         | Mar-2011 | South Korea  | Aug-2012 |             |          |
| Hong Kong              | Dec-2012 | Mexico        | Aug-2014 | Spain        | Mar-2011 |             |          |

Note: The purpose of this document is to demonstrate that Eisai seeks to expand access to its products for patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

## Halaven Approval Status Worldwide (Country/ Region)

April, 2019

### Breast Cancer, 2nd line

|                        |          |               |          |             |          |
|------------------------|----------|---------------|----------|-------------|----------|
| Australia              | Nov-2015 | Ireland       | Jun-2014 | Poland      | Jun-2014 |
| Austria                | Jun-2014 | Israel        | Nov-2014 | Portugal    | Jun-2014 |
| Belgium                | Jun-2014 | Italy         | Jun-2014 | Romania     | Jun-2014 |
| Bosnia and Herzegovina | Sep-2015 | Kuwait        | Sep-2018 | Russia      | Nov-2014 |
| Brazil                 | Sep-2018 | Latvia        | Jun-2014 | Serbia      | Feb-2018 |
| Bulgaria               | Jun-2014 | Lebanon       | Feb-2018 | Slovakia    | Jun-2014 |
| Cambodia               | Oct-2017 | Liechtenstein | Jun-2014 | Slovenia    | Jun-2014 |
| Croatia                | Jun-2014 | Lithuania     | Jun-2014 | South Korea | -2015    |
| Cyprus                 | Jun-2014 | Luxembourg    | Jun-2014 | Spain       | Jun-2014 |
| Czech Republic         | Jun-2014 | Macau         | Apr-2015 | Sri Lanka   | Jan-2019 |
| Denmark                | Jun-2014 | Malaysia      | May-2018 | Sweden      | Jun-2014 |
| Estonia                | Jun-2014 | Malta         | Jun-2014 | Switzerland | Jul-2014 |
| Finland                | Jun-2014 | Mexico        | Mar-2018 | Thailand    | Aug-2014 |
| France                 | Jun-2014 | Morocco       | Dec-2014 | UAE         | Nov-2018 |
| Germany                | Jun-2014 | Myanmar       | Oct-2015 | UK          | Jun-2014 |
| Greece                 | Jun-2014 | Namibia       | Aug-2018 |             |          |
| Hong Kong              | Oct-2014 | Netherlands   | Jun-2014 |             |          |
| Hungary                | Jun-2014 | Norway        | Jun-2014 |             |          |
| Iceland                | Jun-2014 | Pakistan      | Jan-2019 |             |          |
| India                  | Feb-2015 | Philippines   | Sep-2014 |             |          |

Halaven®は日本において、手術不能又は再発乳がんの適応で製造販売承認を取得しました。

Note: The purpose of this document is to demonstrate that Eisai seeks to expand access to its products for patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

## Halaven Approval Status Worldwide (Country/ Region)

April, 2019

### Soft Tissue Sarcoma

|                        |          |               |          |             |          |
|------------------------|----------|---------------|----------|-------------|----------|
| Australia              | Nov-2016 | Indonesia     | Jun-2018 | Pakistan    | Jan-2019 |
| Austria                | May-2016 | Ireland       | May-2016 | Philippines | May-2016 |
| Belgium                | May-2016 | Israel        | Oct-2016 | Poland      | May-2016 |
| Bosnia and Herzegovina | Feb-2018 | Italy         | May-2016 | Portugal    | May-2016 |
| Brazil                 | Sep-2018 | Japan         | Feb-2016 | Romania     | May-2016 |
| Bulgaria               | May-2016 | Kuwait        | Sep-2018 | Russia      | Jun-2016 |
| Canada                 | Aug-2017 | Latvia        | May-2016 | Singapore   | Mar-2017 |
| Croatia                | May-2016 | Lebanon       | Feb-2018 | Slovakia    | May-2016 |
| Cyprus                 | May-2016 | Liechtenstein | May-2016 | Slovenia    | May-2016 |
| Czech Republic         | May-2016 | Lithuania     | May-2016 | South Korea | Jan-2017 |
| Denmark                | May-2016 | Luxembourg    | May-2016 | Spain       | May-2016 |
| Estonia                | May-2016 | Macau         | Jun-2017 | Sri Lanka   | Jan-2019 |
| Finland                | May-2016 | Malaysia      | May-2018 | Sweden      | May-2016 |
| France                 | May-2016 | Malta         | May-2016 | Switzerland | Dec-2016 |
| Germany                | May-2016 | Mexico        | Mar-2018 | Taiwan      | Nov-2016 |
| Greece                 | May-2016 | Morocco       | May-2018 | Thailand    | Sep-2017 |
| Hong Kong              | Feb-2017 | Myanmar       | Oct-2018 | UAE         | Nov-2018 |
| Hungary                | May-2016 | Namibia       | Aug-2018 | US          | Jan-2016 |
| Iceland                | May-2016 | Netherlands   | May-2016 | UK          | May-2016 |
| India                  | Oct-2016 | Norway        | May-2016 |             |          |

Note: The purpose of this document is to demonstrate that Eisai seeks to expand access to its products for patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.